Gemcitabine has been extensively evaluated across numerous clinical trials spanning Phase 1 through Phase 4 for indications including pancreatic, biliary tract, serous ovarian, non-small cell lung, osteosarcoma, and nasopharyngeal cancers. Sponsored by diverse organizations—including academic medical centers, hospital networks, and biopharmaceutical companies—these investigations reflect varied recruitment statuses ranging from completed and active to recruiting and not yet recruiting. Ultimately, this extensive clinical landscape underscores gemcitabine's broad utility in combination oncology regimens.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07528768 | NOT_YET_RECRUITING | Triple Negative Breast Cancer; Metastatic Triple-negative Breast Cancer |
AntiCancer Research Jamaica |
2026-06-01 | PHASE2 |
| NCT04198766 | RECRUITING | Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer |
Inhibrx Biosciences, Inc |
2019-12-10 | PHASE1; PHASE2 |
| NCT06714604 | RECRUITING | Locally Advanced Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Carcinoma; Pancreas Cancer; Neoadjuvant Chemotherapy; Surgery; Pancreatectomy |
Sahlgrenska University Hospital |
2023-10-18 | PHASE3 |
| NCT05919537 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor |
Hummingbird Bioscience |
2023-09-06 | PHASE1 |
| NCT06608927 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Arcus Biosciences, Inc. |
2024-12-13 | PHASE3 |
| NCT07184788 | NOT_YET_RECRUITING | Aggressive B-Cell Lymphoma |
Navy General Hospital, Beijing |
2025-10-01 | PHASE2 |
| NCT07001618 | RECRUITING | NSCLC (Advanced Non-small Cell Lung Cancer) |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-11-17 | PHASE2 |
| NCT07155629 | NOT_YET_RECRUITING | Pancreatic Cancer Resectable |
Helsinki University Central Hospital |
2025-09-01 | PHASE3 |
| NCT05538663 | ACTIVE_NOT_RECRUITING | Non-muscle-invasive Bladder Cancer |
ECOG-ACRIN Cancer Research Group |
2023-02-07 | PHASE3 |
| NCT07365306 | RECRUITING | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma |
City of Hope Medical Center |
2026-07-27 | PHASE2 |
| NCT04796220 | ACTIVE_NOT_RECRUITING | Breast Cancer; Breast Neoplasms |
Patrick Dillon, MD |
2022-01-27 | PHASE1 |
| NCT07683221 | NOT_YET_RECRUITING | Pancreatic Cancer |
Shandong Cancer Hospital and Institute |
2026-07-15 | PHASE2 |
| NCT07028424 | NOT_YET_RECRUITING | PDAC - Pancreatic Ductal Adenocarcinoma |
GERCOR - Multidisciplinary Oncology Cooperative Group |
2025-07 | PHASE2 |
| NCT07129993 | RECRUITING | Urothelial Cancer; Bladder Cancer |
Daiichi Sankyo |
2025-09-26 | PHASE2; PHASE3 |
| NCT07076121 | ACTIVE_NOT_RECRUITING | Pancreatic Ductal Adenocarcinoma |
Bristol-Myers Squibb |
2025-10-23 | PHASE2; PHASE3 |
| NCT06632327 | ACTIVE_NOT_RECRUITING | Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology |
2024-12-11 | PHASE3 |
| NCT05979961 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2023-09-07 | PHASE3 |
| NCT07578337 | NOT_YET_RECRUITING | Untreated; Advanced Pancreatic Cancer |
Nelum Corp |
2026-07-15 | PHASE2 |
| NCT07106762 | RECRUITING | Urothelial Cancer |
Bristol-Myers Squibb |
2025-09-30 | PHASE2; PHASE3 |
| NCT07277452 | NOT_YET_RECRUITING | Pancreatic Cancer, Adult |
The First Affiliated Hospital with Nanjing Medical University |
2025-12-10 | PHASE2 |
| NCT07226856 | RECRUITING | Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 |
Mayo Clinic |
2025-12-12 | PHASE2 |
| NCT07036380 | RECRUITING | Advanced Biliary Tract Carcinoma |
Centre Hospitalier Universitaire de Besancon |
2025-12-22 | PHASE2 |
| NCT07213804 | RECRUITING | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-10-22 | PHASE3 |
| NCT07238283 | RECRUITING | First-line Treatment of Metastatic Pancreatic Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2025-12-02 | PHASE3 |
| NCT06904378 | RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Washington University School of Medicine |
2026-03-25 | PHASE1; PHASE2 |
| NCT06561763 | NOT_YET_RECRUITING | High Risk Locally Advanced Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2024-08-20 | PHASE3 |
| NCT06204614 | ENROLLING_BY_INVITATION | Muscle Invasive Bladder Urothelial Carcinoma |
Brigham and Women's Hospital |
2024-06-14 | EARLY_PHASE1 |
| NCT07445295 | NOT_YET_RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Chipscreen Biosciences, Ltd. |
2026-03-31 | PHASE3 |
| NCT04241276 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer |
Queen Mary University of London |
2020-04-30 | PHASE2 |
| NCT06459180 | ACTIVE_NOT_RECRUITING | Cervical Cancer |
Merck Sharp & Dohme LLC |
2024-07-24 | PHASE3 |
| NCT07252375 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma (NPC); CTIT-Chemotherapy Induced Thrombocytopenia |
Fujian Cancer Hospital |
2025-11-30 | PHASE2 |
| NCT07685470 | NOT_YET_RECRUITING | Pancreatic Ductal Adenocarcinoma (PDAC); Second Line Treatment |
Peking Union Medical College Hospital |
2026-06-08 | PHASE1; PHASE2 |
| NCT07144254 | RECRUITING | Osteosarcoma Recurrent; Osteosarcoma in Children; Relapsed Osteosarcoma; Refractory Osteosarcoma |
Emory University |
2026-01-22 | PHASE1 |
| NCT06929286 | RECRUITING | Non-Muscle Invasive Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
2025-04-11 | PHASE3 |
| NCT06926868 | RECRUITING | Breast Neoplasms |
Bristol-Myers Squibb |
2025-09-11 | PHASE2; PHASE3 |
| NCT06508658 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma |
Genmab |
2024-08-13 | PHASE3 |
| NCT07480850 | ACTIVE_NOT_RECRUITING | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2026-01-01 | PHASE2 |
| NCT05601440 | RECRUITING | Breast Cancer |
Canadian Cancer Trials Group |
2023-06-13 | PHASE2 |
| NCT07598318 | NOT_YET_RECRUITING | Cholangiocarcinoma |
Sir Run Run Shaw Hospital |
2026-05-20 | PHASE2; PHASE3 |
| NCT06692491 | NOT_YET_RECRUITING | Rare Tumour |
Peking University Shenzhen Hospital |
2025-01-01 | PHASE2 |
| NCT07705919 | NOT_YET_RECRUITING | Borderline Resectable Pancreatic Ductal Adenocarcinoma |
Ohio State University Comprehensive Cancer Center |
2026-09-01 | PHASE1; PHASE2 |
| NCT06629597 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
MediLink Therapeutics (Suzhou) Co., Ltd. |
2024-12-31 | PHASE3 |
| NCT07229586 | RECRUITING | Solid Tumor |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
2025-12-02 | PHASE1; PHASE2 |
| NCT07451652 | RECRUITING | Relapsed/Refractory Diffuse Large B Cell Lymphoma |
Hospital Universitario Dr. Jose E. Gonzalez |
2026-03-17 | PHASE2 |
| NCT06483555 | RECRUITING | Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm |
UNC Lineberger Comprehensive Cancer Center |
2025-02-06 | PHASE1; PHASE2 |
| NCT06962267 | RECRUITING | Pancreatic Cancer |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
2025-04-18 | PHASE2 |
| NCT07030140 | RECRUITING | Cholangiocarcinoma; Hilar Cholangiocarcinoma; Bile Duct Cancer |
Jinbo Yue |
2025-07-01 | PHASE2 |
| NCT06752811 | RECRUITING | Pancreatic Cancer Metastatic |
Shanghai Yizhong Pharmaceutical Co., Ltd. |
2025-02-05 | PHASE3 |
| NCT06502080 | NOT_YET_RECRUITING | Biliary Tract Cancer |
Shanghai Zhongshan Hospital |
2024-07 | PHASE2 |
| NCT05096663 | ACTIVE_NOT_RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
SWOG Cancer Research Network |
2022-03-15 | PHASE2; PHASE3 |
| NCT07302841 | NOT_YET_RECRUITING | Pancreatic Cancer Non-resectable |
Tianjin Medical University Cancer Institute and Hospital |
2026-01-20 | PHASE4 |
| NCT04999761 | RECRUITING | Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer |
Taiho Pharmaceutical Co., Ltd. |
2021-06-01 | PHASE1 |
| NCT06851247 | RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2025-01-03 | PHASE2 |
| NCT05999994 | RECRUITING | Neoplasms; Child; Adolescent |
Eli Lilly and Company |
2020-01-22 | PHASE2 |
| NCT06710288 | RECRUITING | Platinum-resistant Ovarian Cancer |
ImmunityBio, Inc. |
2024-11-06 | PHASE2 |
| NCT02151084 | ACTIVE_NOT_RECRUITING | Biliary Tract Carcinoma; Gallbladder Carcinoma |
University Health Network, Toronto |
2014-11 | PHASE2 |
| NCT06888674 | NOT_YET_RECRUITING | Pancreatic Cancer Resectable |
Zhejiang University |
2025-04-01 | PHASE1; PHASE2 |
| NCT06494514 | RECRUITING | Locally Advanced Pancreatic Cancer |
Du Juan |
2024-04-01 | |
| NCT05101551 | RECRUITING | Acute Myeloid Leukemia |
Norman J. Lacayo |
2023-02-23 | PHASE1 |
| NCT07549958 | RECRUITING | Pancreatic Cancer; Pancreatic Cancer Metastatic |
University of California, Irvine |
2026-03-24 | PHASE1 |
| NCT04158635 | SUSPENDED | Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma |
City of Hope Medical Center |
2021-09-01 | PHASE1 |
| NCT06983210 | RECRUITING | Urothelial Carcinoma Bladder; Urothelial Carcinoma of the Renal Pelvis and Ureter; Urothelial Carcinoma Urethra; Urothelial Carcinoma Recurrent |
Nagoya University |
2025-05-01 | PHASE2 |
| NCT06239727 | RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2024-03-01 | PHASE3 |
| NCT05497778 | ACTIVE_NOT_RECRUITING | Pancreas Cancer |
M.D. Anderson Cancer Center |
2022-10-21 | PHASE1 |
| NCT06770452 | RECRUITING | Metastatic Pancreatic Carcinoma |
Zhejiang University |
2025-03-25 | PHASE2 |
| NCT04241185 | ACTIVE_NOT_RECRUITING | Urinary Bladder Neoplasms |
Merck Sharp & Dohme LLC |
2020-05-19 | PHASE3 |
| NCT06234072 | NOT_YET_RECRUITING | Pancreatic Cancer |
Shenzhen University General Hospital |
2024-02 | PHASE2 |
| NCT05823311 | RECRUITING | Advanced Cholangiocarcinoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-09-01 | PHASE3 |
| NCT05969171 | RECRUITING | Pancreatic Cancer Metastatic |
Fudan University |
2023-12-05 | PHASE2 |
| NCT07025174 | RECRUITING | Bile Duct Carcinoma; Gall Bladder Cancer; Biliary Tract Cancer; Cholangiocarcinoma |
First Affiliated Hospital of Zhejiang University |
2025-06-01 | PHASE2 |
| NCT07014943 | RECRUITING | Primary Central Nervous System Lymphoma (PCNSL) |
Sichuan University |
2022-01-01 | PHASE2 |
| NCT05668884 | RECRUITING | Biliary Tract Carcinoma |
Fudan University |
2022-10-18 | PHASE2 |
| NCT05653453 | RECRUITING | Locally Advanced Pancreatic Cancer |
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd |
2022-12-20 | PHASE3 |
| NCT05281471 | RECRUITING | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma |
Genelux Corporation |
2022-08-31 | PHASE3 |
| NCT06623162 | NOT_YET_RECRUITING | Mibc; Muscle Invasive Bladder Cancer |
Fundación de investigación HM |
2024-12 | PHASE2 |
| NCT06202261 | RECRUITING | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-04-13 | PHASE1; PHASE2 |
| NCT06156514 | RECRUITING | Locally Advanced Cervical Cancer; Gemcitabine; Chemo-radiotherapy |
National Institute of Cancerología |
2019-11-06 | PHASE3 |
| NCT06611345 | RECRUITING | Biliary Tract Cancers (BTC) |
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd |
2024-10-21 | |
| NCT06447662 | ACTIVE_NOT_RECRUITING | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-06-27 | PHASE1 |
| NCT05451043 | RECRUITING | Pancreatic Cancer; Hepatocellular Cancer; Biliary Tract Cancer; Cholangiocarcinoma |
AHS Cancer Control Alberta |
2023-07-05 | PHASE2 |
| NCT03440450 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors; Biliary Tract Cancer |
Fujifilm Pharmaceuticals U.S.A., Inc. |
2018-03-22 | PHASE1 |
| NCT06114225 | RECRUITING | Osteosarcoma |
Ruijin Hospital |
2023-06-01 | PHASE2 |
| NCT07138989 | NOT_YET_RECRUITING | Nasopharyngeal Cancinoma (NPC) |
Sun Yat-sen University |
2025-08-19 | PHASE2 |
| NCT04966663 | RECRUITING | Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA |
University Health Network, Toronto |
2022-03-28 | PHASE2 |
| NCT06584227 | RECRUITING | Pancreatic Cancer, Adult |
Liu Xiufeng |
2024-09-10 | PHASE2 |
| NCT05065957 | RECRUITING | Biliary Tract Cancer |
InnoPharmax Inc. |
2022-03-29 | PHASE2; PHASE3 |
| NCT06162468 | NOT_YET_RECRUITING | Intraductal Papillary Mucinous Neoplasm of Pancreas |
University of Auckland, New Zealand |
2025-05-31 | |
| NCT06704724 | TERMINATED | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-12-10 | PHASE1 |
| NCT06398587 | WITHDRAWN | Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2024-08-01 | PHASE2 |
| NCT04481204 | WITHDRAWN | Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma |
M.D. Anderson Cancer Center |
2023-04-18 | PHASE2 |
| NCT06886347 | RECRUITING | Metastatic Nasopharyngeal Carcinoma |
Chen Xiaozhong |
2023-07-07 | PHASE1 |
| NCT06916494 | RECRUITING | Muscle Invasive Bladder Cancer |
First Affiliated Hospital of Chongqing Medical University |
2025-05-01 | PHASE1 |
| NCT05211323 | ACTIVE_NOT_RECRUITING | Combined Hepatocellular Carcinoma and Cholangiocarcinoma; Stage III Liver Cancer; Stage IV Liver Cancer |
National Cancer Institute (NCI) |
2022-12-07 | PHASE2 |
| NCT06382142 | ACTIVE_NOT_RECRUITING | Triple-Negative Breast Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2024-06-21 | PHASE3 |
| NCT06375915 | UNKNOWN | Intrahepatic Cholangiocarcinoma |
Francesco De Cobelli |
2024-05-01 | PHASE2 |
| NCT05241249 | RECRUITING | Pancreas Cancer |
Susan E. Bates |
2022-02-01 | PHASE2 |
| NCT05466318 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell |
Sichuan University |
2022-07-01 | PHASE3 |
| NCT06076837 | TERMINATED | Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma Metastatic |
HonorHealth Research Institute |
2025-01-09 | PHASE1 |
| NCT02170090 | ACTIVE_NOT_RECRUITING | Cholangiocarcinoma; Gall Bladder Carcinoma |
Universitätsklinikum Hamburg-Eppendorf |
2014-04 | PHASE3 |
| NCT06326736 | RECRUITING | Pancreatic Cancer |
Jinling Hospital, China |
2024-04 | EARLY_PHASE1 |
| NCT02705196 | COMPLETED | Pancreatic Cancer |
Lokon Pharma AB |
2016-11 | PHASE1; PHASE2 |
| NCT05527470 | RECRUITING | Nasopharyngeal Carcinoma |
Wei Jiang |
2022-11-11 | PHASE3 |
| NCT06164327 | UNKNOWN | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
BeBetter Med Inc |
2023-12-01 | PHASE1 |
| NCT06086197 | RECRUITING | Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory |
Zhejiang Cancer Hospital |
2023-10-01 | PHASE2 |
| NCT05754853 | RECRUITING | Advanced or Metastatic Urothelium Cancer |
Shanghai Miracogen Inc. |
2023-04-06 | PHASE3 |
| NCT05813626 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
Zhejiang Cancer Hospital |
2023-04-21 | PHASE2 |
| NCT06018883 | UNKNOWN | Metastatic Pancreatic Adenocarcinoma |
Fudan University |
2023-08-20 | PHASE3 |
| NCT01261728 | COMPLETED | Urothelial Carcinoma |
Memorial Sloan Kettering Cancer Center |
2010-12-14 | PHASE2 |
| NCT05325281 | TERMINATED | Pancreas Adenocarcinoma |
Medical College of Wisconsin |
2022-10-31 | PHASE1 |
| NCT03101995 | RECRUITING | Cervical Cancer |
National Institute of Cancerología |
2018-01-16 | PHASE2 |
| NCT06051851 | UNKNOWN | Pancreatic Adenocarcinoma Metastatic |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2023-07-01 | PHASE2 |
| NCT05185869 | UNKNOWN | Pancreatic Cancer |
Ruijin Hospital |
2022-01 | PHASE2 |
| NCT03918278 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2019-06-19 | PHASE1 |
| NCT05189028 | UNKNOWN | Cervical Cancer; Neoadjuvant Chemotherapy |
Chuangzhen Chen |
2021-07-01 | PHASE3 |
| NCT04877587 | WITHDRAWN | Soft Tissue Sarcoma; Bone Sarcoma; Unresectable Soft Tissue Sarcoma; Metastatic Bone Sarcoma; Metastatic Soft-tissue Sarcoma; Unresectable Bone Sarcoma |
David Dickens |
2023-01 | EARLY_PHASE1 |
| NCT05908747 | COMPLETED | Pancreatic Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-05-31 | PHASE2 |
| NCT06472037 | UNKNOWN | Locally Advanced Pancreatic Ductal Adenocarcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2024-07-01 | PHASE2 |
| NCT04898374 | UNKNOWN | Nasopharyngeal Carcinoma |
Kuwait Cancer Control Center |
2021-05-01 | PHASE3 |
| NCT03088540 | COMPLETED | Carcinoma，Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer |
Regeneron Pharmaceuticals |
2017-05-29 | PHASE3 |
| NCT05673811 | COMPLETED | Pancreatic Adenocarcinoma; Metastatic |
Theriva Biologics SL |
2023-01-10 | PHASE2 |
| NCT04832854 | TERMINATED | Non-Small Cell Lung Cancer (NSCLC) |
Hoffmann-La Roche |
2021-04-23 | PHASE2 |
| NCT03002103 | SUSPENDED | Triple-Negative Breast Cancer |
SynCore Biotechnology Co., Ltd. |
2016-11-23 | PHASE3 |
| NCT05171647 | ACTIVE_NOT_RECRUITING | Non-Hodgkin Lymphoma |
Hoffmann-La Roche |
2022-04-25 | PHASE3 |
| NCT04222972 | TERMINATED | RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue |
Hoffmann-La Roche |
2020-07-24 | PHASE3 |
| NCT04617756 | RECRUITING | Urothelial Carcinoma; Cancer |
Centre Hospitalier Universitaire de Nīmes |
2021-09-29 | PHASE2 |
| NCT05178628 | UNKNOWN | Pancreatic Cancer; Thromboembolism |
Michalis Karamouzis |
2022-02-10 | PHASE3 |
| NCT02203760 | ACTIVE_NOT_RECRUITING | Leiomyosarcoma or Carcinosarcoma |
North Eastern German Society of Gynaecological Oncology |
2019-10-16 | PHASE2 |
| NCT04371224 | UNKNOWN | Pancreatic Cancer |
Seoul National University Hospital |
2020-06-23 | PHASE2 |
| NCT05312840 | COMPLETED | Non Small Cell Lung Cancer |
People's Hospital of Quzhou |
2022-01-01 | PHASE4 |
| NCT04447092 | UNKNOWN | Pancreatic Cancer; Chemotherapy Effect |
Seoul National University Hospital |
2020-07-01 | PHASE2 |
| NCT05576272 | UNKNOWN | Nasopharyngeal Carcinoma |
Qilu Pharmaceutical Co., Ltd. |
2022-05-19 | PHASE2; PHASE3 |
| NCT05991518 | UNKNOWN | HER2 Gene Mutation |
SUNHO（China）BioPharmaceutical CO., Ltd. |
2023-04-25 | PHASE1; PHASE2 |
| NCT05651269 | UNKNOWN | NSCLC |
Tiziana Life Sciences LTD |
2023-03-15 | PHASE2 |
| NCT02969083 | UNKNOWN | Upper Tract Urothelial Carcinoma |
The European Uro-Oncology Group |
2018-05-28 | PHASE2 |
| NCT05717790 | RECRUITING | Nasopharyngeal Carcinoma by AJCC V8 Stage |
Fourth Affiliated Hospital of Guangxi Medical University |
2022-12-01 | |
| NCT04787991 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Cancer Insight, LLC |
2021-08-09 | PHASE1 |
| NCT03750669 | COMPLETED | Pancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2018-10-20 | PHASE3 |
| NCT03673072 | COMPLETED | Incidental Gallbladder Carcinoma; Biliary Tract Cancer |
Krankenhaus Nordwest |
2019-07-01 | PHASE3 |
| NCT03366415 | UNKNOWN | Nasopharyngeal Carcinoma |
Chaosu Hu |
2018-01-01 | PHASE3 |
| NCT06533722 | COMPLETED | HER2-negative Metastatic Breast Cancer |
Sun Yat-sen University |
2024-08-04 | PHASE2 |
| NCT05580445 | UNKNOWN | Advanced Pancreatic Cancer |
Shouyao Holdings (Beijing) Co. LTD |
2022-08-11 | PHASE1; PHASE2 |
| NCT05415917 | WITHDRAWN | Pancreatic Cancer |
Rutgers, The State University of New Jersey |
2022-07-29 | PHASE2 |
| NCT04643405 | TERMINATED | Advanced Pancreatic Cancer |
Ascentage Pharma Group Inc. |
2021-03-17 | PHASE1; PHASE2 |
| NCT04247165 | COMPLETED | Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer |
Herlev Hospital |
2020-06-02 | PHASE1; PHASE2 |
| NCT04799249 | COMPLETED | TNBC - Triple-Negative Breast Cancer; Breast Cancer |
G1 Therapeutics, Inc. |
2021-05-14 | PHASE3 |
| NCT04289792 | UNKNOWN | Pancreatic Neoplasms |
Fujian Medical University Union Hospital |
2020-05-09 | PHASE2 |
| NCT03789864 | TERMINATED | Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides |
Indiana University |
2019-10-07 | |
| NCT04203160 | TERMINATED | Biliary Tract Cancer |
University of Michigan Rogel Cancer Center |
2020-06-23 | PHASE1; PHASE2 |
| NCT06320301 | Recruiting | Biliary Tract Cancer|Gemox Chemotherapy |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Suzhou Suncadia Biopharmaceuticals Co. Ltd. |
2024-04-01 | Phase 2 |
| NCT02885974 | COMPLETED | Bladder Cancer |
Baylor College of Medicine |
2016-12 | PHASE1 |
| NCT06046794 | Not yet recruiting | Cancer Of Pancreas |
Institut Paoli-Calmettes |
2024-02-01 | Not Applicable |
| NCT04156087 | COMPLETED | Pancreatic Cancer Non-resectable |
Baki Topal |
2020-05-09 | PHASE2 |
| NCT05186558 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Neoplasms by Histologic Type |
The First Affiliated Hospital with Nanjing Medical University |
2022-05-15 | PHASE2 |
| NCT06199466 | Recruiting | Metastatic Pancreatic Cancer |
M.D. Anderson Cancer Center|280Bio Inc |
2024-01-22 | Phase 1 |
| NCT04890522 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma; Metastasis; Chemotherapy; Immunotherapy; Survival |
Sun Yat-sen University |
2021-07-01 | PHASE2; PHASE3 |
| NCT01972919 | COMPLETED | Unresectable Pancreatic Cancer |
Medical College of Wisconsin |
2015-12-10 | PHASE2 |
| NCT04668976 | UNKNOWN | Colorectal Cancer; Cholangiocarcinoma |
Benaroya Research Institute |
2020-11-25 | PHASE2 |
| NCT00657878 | UNKNOWN | Ovarian Cancer |
National Cancer Institute, Naples |
2008-11 | PHASE3 |
| NCT04871529 | TERMINATED | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8 |
SWOG Cancer Research Network |
2022-08-10 | PHASE2 |
| NCT06055348 | Not yet recruiting | Serous Ovarian Cancer|Advanced Ovarian Cancer |
Biocity Biopharmaceutics Co. Ltd. |
2023-10-30 | Phase 1|Phase 2 |
| NCT05030077 | UNKNOWN | Urothelial Carcinoma; Anlotinib; Urogenital Neoplasms; Cisplatin; Carboplatin; Gemcitabine; Antineoplastic Agents |
Tianjin Medical University Second Hospital |
2021-10-01 | PHASE2 |
| NCT05138159 | UNKNOWN | Metastatic Pancreatic Cancer |
Fudan University |
2021-12-01 | PHASE2 |
| NCT04023669 | COMPLETED | Brain Tumor; Brain Tumor, Recurrent; Brain Tumor, Refractory; Brain Tumor, Pediatric; Medulloblastoma; Medulloblastoma Recurrent; Medulloblastoma, Non-WNT/Non-SHH; Medulloblastoma, Non-WNT/Non-SHH, Group 3; Medulloblastoma, Non-WNT/Non-SHH, Group 4; Brain Cancer; CNS Cancer; CNS Tumor; CNS Neoplasm |
St. Jude Children's Research Hospital |
2019-08-08 | PHASE1 |
| NCT03260712 | COMPLETED | Biliary Tract Cancer; Metastatic Cancer; Advanced Cancer; Gallbladder Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2020-01-07 | PHASE2 |
| NCT03435250 | TERMINATED | Advanced Solid Tumors; Lymphoma |
Institut de Recherches Internationales Servier |
2018-03-04 | PHASE1 |
| NCT04887831 | TERMINATED | Urothelial Carcinoma; Bladder Cancer; Myelosuppression Adult; Chemotherapy-induced Neutropenia; Metastatic Bladder Cancer |
G1 Therapeutics, Inc. |
2021-06-04 | PHASE2 |
| NCT04948788 | UNKNOWN | Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma |
Jiangsu HengRui Medicine Co., Ltd. |
2021-10 | PHASE2 |
| NCT07411144 | COMPLETED | Diffuse Pleural Mesothelioma (DPM) |
National Cancer Institute, Egypt |
2020-03-15 | PHASE2 |
| NCT04846634 | NOT_YET_RECRUITING | Resectable Locally Advanced Non-small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-08 | PHASE2 |
| NCT04405622 | UNKNOWN | Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Carcinoma; Chemotherapy Effect; Immunotherapy |
Sun Yat-sen University |
2020-05-30 | PHASE2 |
| NCT02167711 | COMPLETED | Cholangio Carcinoma |
Chinese University of Hong Kong |
2014-09-17 | PHASE2 |
| NCT03251313 | UNKNOWN | Triple Negative Breast Cancer |
Fudan University |
2019-05-15 | PHASE1 |
| NCT04331626 | UNKNOWN | Non-small Cell Lung Cancer Metastatic |
Henan Cancer Hospital |
2020-04 | PHASE4 |
| NCT03666832 | UNKNOWN | Metastatic Pancreatic Cancer |
Joon Oh Park |
2019-06-17 | PHASE1; PHASE2 |
| NCT04306900 | COMPLETED | Solid Tumor, Adult |
Trishula Therapeutics, Inc. |
2020-03-30 | PHASE1 |
| NCT02621151 | ACTIVE_NOT_RECRUITING | Muscle-invasive Urothelial Cancer of the Bladder |
NYU Langone Health |
2016-08-11 | PHASE2 |
| NCT04581343 | COMPLETED | Metastatic Pancreatic Ductal Adenocarcinoma |
Pancreatic Cancer Action Network |
2020-11-02 | PHASE1 |
| NCT04386746 | ACTIVE_NOT_RECRUITING | Urothelial Carcinoma Bladder; Bladder Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-07-29 | PHASE2 |
| NCT03535727 | COMPLETED | Adenocarcinoma; Pancreatic Neoplasms; Neoplasm, Glandular; Neoplasms; Neoplasms Pancreatic; Digestive System Neoplasm; Endocrine Gland Neoplasms; Digestive System Disease; Pancreatic Diseases; Endocrine System Diseases |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2018-06-21 | PHASE1; PHASE2 |
| NCT02426281 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Samsung Medical Center |
2015-06-04 | PHASE2 |
| NCT03432741 | TERMINATED | Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7 |
Mayo Clinic |
2018-03-27 | PHASE1 |
| NCT02635971 | UNKNOWN | Carcinoma, Pancreatic |
Fudan University |
2015-12 | PHASE2 |
| NCT04414566 | UNKNOWN | Nasopharyngeal Carcinoma |
West China Hospital |
2020-06-01 | PHASE3 |
| NCT03081039 | WITHDRAWN | Intrahepatic Cholangiocarcinoma |
University of Louisville |
2017-08-21 | PHASE3 |
| NCT03943667 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
UNICANCER |
2019-05-23 | PHASE3 |
| NCT03519308 | TERMINATED | Pancreatic Cancer |
Abramson Cancer Center at Penn Medicine |
2020-07-29 | EARLY_PHASE1 |
| NCT04480190 | WITHDRAWN | Cholangiocarcinoma; Biliary Cancer |
Jordan Kharofa |
2021-02-04 | PHASE1 |
| NCT03539328 | UNKNOWN | Ovarian Cancer |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2018-06 | PHASE2 |
| NCT03674242 | TERMINATED | Triple Negative Breast Cancer |
ERYtech Pharma |
2019-06-13 | PHASE2; PHASE3 |
| NCT03737123 | TERMINATED | Urothelial Carcinoma |
Nabil Adra |
2018-12-19 | PHASE2 |
| NCT02564146 | COMPLETED | Metastatic Pancreatic Cancer; Adenocarcinoma of the Pancreas |
AIO-Studien-gGmbH |
2016-12 | PHASE2 |
| NCT02578641 | COMPLETED | Nasopharyngeal Carcinoma |
Tessa Therapeutics |
2014-07 | PHASE3 |
| NCT04470076 | UNKNOWN | Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2020-07-10 | PHASE2 |
| NCT01897454 | TERMINATED | Pancreatic Adenocarcinoma; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer |
Albert Einstein College of Medicine |
2012-01-27 | PHASE2 |
| NCT04313608 | COMPLETED | B-cell Lymphoma |
Hoffmann-La Roche |
2020-06-04 | PHASE1 |
| NCT00370890 | COMPLETED | Nasopharyngeal Cancer |
Chinese University of Hong Kong |
2006-09-04 | PHASE3 |
| NCT02611037 | COMPLETED | Malignant Pleural Mesothelioma; Mesothelioma |
H. Lee Moffitt Cancer Center and Research Institute |
2016-03-04 | PHASE2 |
| NCT03703063 | UNKNOWN | Pancreatic Adenocarcinoma |
Benaroya Research Institute |
2018-09-17 | PHASE1 |
| NCT02926183 | UNKNOWN | Pancreatic Ductal Adenocarcinoma |
Wakayama Medical University |
2016-10 | PHASE2 |
| NCT02918747 | UNKNOWN | Lymphoma |
Hunan Cancer Hospital |
2016-09 | PHASE2 |
| NCT03707509 | UNKNOWN | Nasopharyngeal Carcinoma |
Jiangsu HengRui Medicine Co., Ltd. |
2018-11-13 | PHASE3 |
| NCT03071822 | UNKNOWN | Peripheral T Cell Lymphoma |
The University of Hong Kong |
2017-02-24 | PHASE4 |
| NCT02822157 | UNKNOWN | Ovarian Epithelial Cancer |
Universitaire Ziekenhuizen KU Leuven |
2016-08 | PHASE2 |
| NCT04917250 | UNKNOWN | Extranodal NK/T-cell Lymphoma |
Beijing Tongren Hospital |
2020-03-20 | PHASE2 |
| NCT02550327 | COMPLETED | Pancreatic Adenocarcinoma |
Baylor Research Institute |
2016-01 | EARLY_PHASE1 |
| NCT03684811 | COMPLETED | Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme); Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations |
Forma Therapeutics, Inc. |
2018-11-01 | PHASE1; PHASE2 |
| NCT04066491 | TERMINATED | Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer |
EMD Serono Research & Development Institute, Inc. |
2019-09-20 | PHASE2; PHASE3 |
| NCT04299880 | COMPLETED | Oncology |
Sumitomo Pharma America, Inc. |
2020-02-24 | PHASE1 |
| NCT06440187 | COMPLETED | Recurrent or Metastatic Nasopharyngeal Carcinom |
Seoul National University Hospital |
2018-06-08 | PHASE2 |
| NCT03488251 | TERMINATED | Non-hodgkin Lymphoma,B Cell; Refractory Diffuse Large B-Cell Lymphoma; Relapsed Diffuse Large B-Cell Lymphoma |
Molecular Templates, Inc. |
2018-08-20 | PHASE2 |
| NCT03214250 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Parker Institute for Cancer Immunotherapy |
2017-07-21 | PHASE1; PHASE2 |
| NCT04054362 | COMPLETED | Pancreatic Cancer |
Barts & The London NHS Trust |
2018-11-29 | PHASE2 |
| NCT03086369 | COMPLETED | Metastatic Pancreatic Cancer |
Eli Lilly and Company |
2017-06-22 | PHASE1; PHASE2 |
| NCT03366766 | TERMINATED | Non-Squamous Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2017-12-20 | PHASE2 |
| NCT04750382 | UNKNOWN | Triple-negative Breast Cancer |
Taizhou Hanzhong biomedical co. LTD |
2019-07-15 | PHASE1; PHASE2 |
| NCT02490488 | COMPLETED | Ovarian Cancer |
AB Science |
2014-04 | PHASE2; PHASE3 |
| NCT02627807 | UNKNOWN | Nasopharyngeal Neoplasms |
Sun Yat-sen University |
2015-12 | |
| NCT03717155 | COMPLETED | Squamous Non-Small Cell Lung Cancer |
Merck KGaA, Darmstadt, Germany |
2018-10-30 | PHASE2 |
| NCT01595061 | UNKNOWN | Stage III Vulvar Cancer AJCC v7; Stage IIIA Vulvar Cancer AJCC v7; Stage IIIB Vulvar Cancer AJCC v7; Stage IIIC Vulvar Cancer AJCC v7; Stage IVA Vulvar Cancer AJCC v7; Vulvar Squamous Cell Carcinoma |
Gynecologic Oncology Group |
2012-07-02 | PHASE2 |
| NCT00769483 | COMPLETED | Pancreatic Cancer; Pancreatic Adenocarcinoma |
M.D. Anderson Cancer Center |
2008-11-13 | PHASE1; PHASE2 |
| NCT02392637 | COMPLETED | Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma |
M.D. Anderson Cancer Center |
2015-04-02 | PHASE2 |
| NCT03636308 | UNKNOWN | Pancreatic Cancer |
Peking University |
2018-07-17 | PHASE2 |
| NCT03486678 | COMPLETED | Biliary Tract Cancer; Cholangiocarcinoma |
The First Affiliated Hospital with Nanjing Medical University |
2018-02-10 | PHASE2 |
| NCT03601975 | UNKNOWN | Nasopharyngeal Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2018-08-27 | PHASE3 |
| NCT03517176 | COMPLETED | Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma |
Lisata Therapeutics, Inc. |
2018-07-31 | PHASE1 |
| NCT03559348 | COMPLETED | Pancreatic Adenocarcinoma |
National Health Research Institutes, Taiwan |
2018-04-03 | PHASE2 |
| NCT02363751 | COMPLETED | Collecting Duct Carcinoma (Kidney) |
UNICANCER |
2014-12 | PHASE2 |
| NCT02993731 | COMPLETED | Carcinoma, Pancreatic Ductal |
Sumitomo Pharma America, Inc. |
2016-12 | PHASE3 |
| NCT03464968 | COMPLETED | Biliary Cancer Metastatic |
Seoul National University Bundang Hospital |
2015-07-29 | PHASE2 |
| NCT03628521 | UNKNOWN | Lung Cancer; Advanced Stage |
Shanghai Chest Hospital |
2018-07-20 | PHASE1 |
| NCT02009332 | COMPLETED | Non-muscle Invasive Bladder Cancer (NMIBC) |
Aadi Bioscience, Inc. |
2014-04-09 | PHASE1; PHASE2 |
| NCT02427841 | COMPLETED | Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma |
OHSU Knight Cancer Institute |
2016-01-21 | PHASE2 |
| NCT01270724 | COMPLETED | CNS Germ Cell Tumor |
Nationwide Children's Hospital |
2010-08 | PHASE2 |
| NCT05517239 | COMPLETED | Hepatocellular Carcinoma, Unresectable, Advanced |
Yonsei University |
2015-05-01 | PHASE2 |
| NCT02878889 | UNKNOWN | Nasopharyngeal Carcinoma |
Zhejiang Cancer Hospital |
2016-08 | PHASE2 |
| NCT03344172 | TERMINATED | Pancreatic Cancer Resectable |
Nathan Bahary, MD |
2017-12-13 | PHASE2 |
| NCT03236883 | UNKNOWN | Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV |
Tianjin Medical University Cancer Institute and Hospital |
2016-04 | PHASE1 |
| NCT03307148 | COMPLETED | Pancreatic Adenocarcinoma |
Barts & The London NHS Trust |
2016-01-15 | PHASE1 |
| NCT01309633 | COMPLETED | Nasopharyngeal Carcinoma |
National University Hospital, Singapore |
2011-09-02 | PHASE2 |
| NCT02162914 | UNKNOWN | Cholangiocarcinoma |
Erasme University Hospital |
2014-03-14 | PHASE2 |
| NCT01077427 | UNKNOWN | Resected Pancreatic Adenocarcinoma |
Klinikum der Universitaet Muenchen, Grosshadern |
2012-03 | PHASE3 |
| NCT03432598 | COMPLETED | Locally Advanced Lung Cancer; Metastatic Lung Cancer |
BeiGene |
2017-08-24 | PHASE2 |
| NCT02272790 | COMPLETED | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation |
AstraZeneca |
2015-01-30 | PHASE2 |
| NCT03848182 | TERMINATED | Pancreatic Cancer |
Albert Einstein College of Medicine |
2017-07-21 | PHASE2 |
| NCT01872962 | UNKNOWN | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2013-11 | PHASE3 |
| NCT02453282 | ACTIVE_NOT_RECRUITING | Non-Small-Cell Lung Carcinoma NSCLC |
AstraZeneca |
2015-07-21 | PHASE3 |
| NCT02114502 | WITHDRAWN | Myeloma |
M.D. Anderson Cancer Center |
2014-09 | PHASE2 |
| NCT02412670 | COMPLETED | High Grade Upper Tract Urothelial Carcinoma |
ECOG-ACRIN Cancer Research Group |
2015-08-27 | PHASE2 |
| NCT01589094 | COMPLETED | Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
2012-04 | PHASE2 |
| NCT03560973 | COMPLETED | Mesothelioma |
Gruppo Oncologico Italiano di Ricerca Clinica |
2016-12-22 | PHASE2 |
| NCT02375880 | COMPLETED | Carcinoma of Intrahepatic and Extra-hepatic Biliary System; Carcinoma of Gallbladder; Bile Duct Cancer; Cholangiocarcinoma |
Leap Therapeutics, Inc. |
2015-06 | PHASE1 |
| NCT02767752 | TERMINATED | Pancreatic Cancer |
Herlev Hospital |
2016-11 | PHASE2 |
| NCT01726582 | COMPLETED | Pancreatic Adenocarcinoma |
Medical College of Wisconsin |
2011-11 | PHASE2 |
| NCT02487277 | TERMINATED | Adenocarcinoma |
Andrew Ko |
2015-07-14 | PHASE2 |
| NCT01442662 | COMPLETED | Leiomyosarcoma |
UNICANCER |
2011-09 | PHASE2 |
| NCT02559674 | COMPLETED | Advanced Pancreatic Cancer |
Altor BioScience |
2016-07 | PHASE1 |
| NCT01376310 | TERMINATED | Cancer |
Novartis Pharmaceuticals |
2010-11-02 | PHASE2 |
| NCT00997906 | UNKNOWN | Head and Neck Cancer |
National Cancer Centre, Singapore |
2009-09-15 | PHASE2; PHASE3 |
| NCT02791373 | COMPLETED | Multiple Myeloma; Amyloidosis |
Insel Gruppe AG, University Hospital Bern |
2014-03 | PHASE2 |
| NCT02409355 | TERMINATED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2015-05-07 | PHASE3 |
| NCT01971281 | UNKNOWN | Pancreatic Adenocarcinoma |
NovoCure Ltd. |
2013-11 | PHASE1; PHASE2 |
| NCT02558868 | COMPLETED | Pancreatic Neoplasms |
Zhejiang University |
2015-09-01 | PHASE2 |
| NCT02300610 | COMPLETED | Bladder Cancer; Carcinoma, Transitional Cell; Renal Pelvis Cancer; Ureter Cancer; Urethra Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2015-02-11 | PHASE1 |
| NCT01524991 | COMPLETED | Urothelial Carcinoma |
Hoosier Cancer Research Network |
2012-01 | PHASE2 |
| NCT01908478 | COMPLETED | Pancreatic Cancer |
Cedars-Sinai Medical Center |
2013-10-02 | PHASE1 |
| NCT02506803 | UNKNOWN | Pancreatic Cancer |
Wakayama Medical University |
2015-07 | PHASE1 |
| NCT01259063 | COMPLETED | Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
2010-12 | PHASE1; PHASE2 |
| NCT02425137 | COMPLETED | Advanced Biliary Tract Cancer(BTC) |
TTY Biopharm |
2015-04 | PHASE2 |
| NCT02514421 | COMPLETED | Pancreatic Adenocarcinoma |
The University of Texas Health Science Center, Houston |
2015-07 | PHASE1 |
| NCT02440958 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Yonsei University |
2015-08-28 | PHASE2 |
| NCT02632019 | UNKNOWN | Advanced Biliary Tract Malignant Tumor |
Second Military Medical University |
2015-09 | PHASE1; PHASE2 |
| NCT01352962 | COMPLETED | Urethral Neoplasms; Neoplasms, Urethral; Cancer of the Urethra; Urethral Cancer |
National Cancer Institute (NCI) |
2011-09-26 | PHASE1 |
| NCT02005419 | COMPLETED | Stage IA Pancreatic Adenocarcinoma; Stage IB Pancreatic Adenocarcinoma; Stage IIA Pancreatic Adenocarcinoma; Stage IIB Pancreatic Adenocarcinoma |
Xian-Jun Yu |
2013-12 | PHASE2 |
| NCT01041781 | TERMINATED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2010-02 | PHASE3 |
| NCT02651727 | TERMINATED | Pancreatic Cancer |
Verastem, Inc. |
2015-09 | PHASE1 |
| NCT02900742 | COMPLETED | Cancer |
Shanghai University of Traditional Chinese Medicine |
2013-03 | PHASE3 |
| NCT02850874 | WITHDRAWN | Pancreatic Neoplasms; Pancreatic Adenocarcinoma |
Wake Forest University Health Sciences |
2016-02 | PHASE2 |
| NCT02581501 | WITHDRAWN | Pancreatic Cancer |
Stamford Hospital |
2016-02 | PHASE1 |
| NCT02207335 | UNKNOWN | Metastatic Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2013-12 | PHASE3 |
| NCT01836432 | TERMINATED | Pancreatic Cancer; Pancreatic Carcinoma Non-resectable; Locally Advanced Malignant Neoplasm |
NewLink Genetics Corporation |
2013-05 | PHASE3 |
| NCT01846390 | COMPLETED | Peripheral T-Cell Lymphoma; Diffuse Large B-Cell Lymphoma |
Canadian Cancer Trials Group |
2013-10-01 | PHASE1 |
| NCT02117258 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Zeria Pharmaceutical |
2014-04 | PHASE2 |
| NCT01549093 | UNKNOWN | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2011-08 | PHASE2 |
| NCT02405585 | TERMINATED | Pancreatic Cancer; Pancreatic Carcinoma Non-resectable |
NewLink Genetics Corporation |
2015-04 | PHASE2 |
| NCT02099396 | UNKNOWN | Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma |
China Association of Osteosarcoma Chemotherapy |
2014-04 | PHASE2; PHASE3 |
| NCT01893801 | COMPLETED | Stage IV Pancreatic Cancer |
Pancreatic Cancer Research Team |
2013-05 | PHASE1; PHASE2 |
| NCT02570711 | TERMINATED | Metastatic Pancreatic Cancer |
Acerta Pharma BV |
2015-10-13 | PHASE2 |
| NCT02245217 | COMPLETED | Pancreatic Cancer |
University of Utah |
2014-12-12 | |
| NCT01206049 | COMPLETED | Cholangiocarcinoma |
Vejle Hospital |
2010-09 | PHASE2 |
| NCT01182168 | COMPLETED | Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer |
Memorial Sloan Kettering Cancer Center |
2010-08 | PHASE1 |
| NCT02182778 | COMPLETED | Biliary Tract Cancer |
Kansai Hepatobiliary Oncology Group |
2014-07-09 | PHASE3 |
| NCT01702714 | WITHDRAWN | Non-Squamous Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2014-07 | PHASE1 |
| NCT01746979 | COMPLETED | Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma |
ImmunoGenesis |
2012-12 | PHASE3 |
| NCT01858883 | COMPLETED | Solid Tumors; Pancreatic Cancer |
Incyte Corporation |
2013-06 | PHASE1; PHASE2 |
| NCT01917617 | COMPLETED | Biliary Tract Cancer |
Kansai Hepatobiliary Oncology Group |
2013-05-22 | PHASE2 |
| NCT02233205 | UNKNOWN | Gastrointestinal Neoplasms |
Peking University Cancer Hospital & Institute |
2014-10 | PHASE1; PHASE2 |
| NCT01501149 | UNKNOWN | Nasal and Nasal-type NK/T-cell Lymphoma |
Mingzhi Zhang |
2011-01 | PHASE4 |
| NCT01191892 | COMPLETED | Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer |
Cardiff University |
2010-06 | PHASE2 |
| NCT01608711 | COMPLETED | Pancreatic Cancer; Carcinoma, Pancreatic Ductal; Pancreatic Disease |
Agensys, Inc. |
2012-08-07 | PHASE2 |
| NCT00733746 | COMPLETED | Pancreatic Cancer |
Alliance for Clinical Trials in Oncology |
2009-04 | PHASE2 |
| NCT00324805 | COMPLETED | Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2007-07-19 | PHASE3 |
| NCT01411072 | UNKNOWN | Pancreas Cancer |
AHS Cancer Control Alberta |
2011-09 | |
| NCT01808638 | COMPLETED | Carcinoma, Pancreatic Ductal |
Silence Therapeutics GmbH |
2013-03 | PHASE1; PHASE2 |
| NCT01936974 | TERMINATED | Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma |
Western Regional Medical Center |
2013-09 | PHASE2 |
| NCT02001896 | UNKNOWN | Non-Small Cell Lung Cancer |
Xinjiang Medical University |
2013-12 | PHASE3 |
| NCT02105350 | WITHDRAWN | Biliary Tract Carcinoma; Gallbladder Carcinoma |
University Health Network, Toronto |
2015-06 | PHASE1 |
| NCT01303029 | COMPLETED | Metastatic Pancreatic Cancer |
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
2011-02 | PHASE2 |
| NCT01487915 | UNKNOWN | Advanced Urothelial Carcinoma |
Asan Medical Center |
2010-10 | PHASE2 |
| NCT02030574 | TERMINATED | Invasive Bladder Cancer; Bladder Cancer |
Brown University |
2014-07 | PHASE2 |
| NCT01510561 | WITHDRAWN | Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer |
Gilead Sciences |
2012-03 | PHASE1 |
| NCT01126749 | TERMINATED | Bladder Cancer |
Eisai Inc. |
2010-04-16 | PHASE1; PHASE2 |
| NCT01007552 | COMPLETED | Cholangiocarcinoma |
Roswell Park Cancer Institute |
2009-12 | PHASE2 |
| NCT01812018 | UNKNOWN | Soft Tissue Sarcoma |
Peng Yuan |
2012-11 | PHASE2 |
| NCT02046304 | COMPLETED | Sarcoma |
M.D. Anderson Cancer Center |
2001-12 | PHASE1 |
| NCT01815242 | COMPLETED | Breast Cancer |
Women's Cancer Study Group GmbH |
2013-06 | PHASE2 |
| NCT01797913 | COMPLETED | THE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer |
Fudan University |
2008-08 | PHASE2 |
| NCT01851174 | TERMINATED | Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer |
Western Regional Medical Center |
2013-02 | PHASE2 |
| NCT01050426 | TERMINATED | Pancreatic Cancer |
Royal Marsden NHS Foundation Trust |
2009-03 | PHASE2 |
| NCT01781988 | COMPLETED | Lung Cancer; Carboplatin Adverse Reaction |
Guangzhou Medical University |
2009-06 | PHASE2 |
| NCT00690872 | UNKNOWN | Head and Neck Cancer |
National Cancer Centre, Singapore |
2008-07 | PHASE2 |
| NCT01426633 | COMPLETED | Leiomyosarcoma; Liposarcoma |
Heidelberg University |
2011-11 | PHASE1 |
| NCT02496832 | WITHDRAWN | Pancreatic Adenocarcinoma; Advanced Disease; Metastatic Disease |
University Health Network, Toronto |
2014-11 | |
| NCT01196559 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer |
The Catholic University of Korea |
2011-01 | PHASE2 |
| NCT01860040 | TERMINATED | Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer; Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer |
Western Regional Medical Center |
2013-04 | PHASE2 |
| NCT01754623 | TERMINATED | Pancreatic Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2013-02 | PHASE2 |
| NCT00948935 | COMPLETED | Biliary Cancer; Cholangiocarcinoma |
Abramson Cancer Center at Penn Medicine |
2009-04 | PHASE2 |
| NCT01483300 | UNKNOWN | Breast Cancer |
Harbin Medical University |
2011-11 | PHASE2 |
| NCT00949949 | COMPLETED | Cholangiocarcinoma of the Gallbladder; Localized Gallbladder Cancer; Unresectable Gallbladder Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
Mayo Clinic |
2009-09 | PHASE1 |
| NCT00733850 | COMPLETED | Pancreatic Cancer |
KangLaiTe USA |
2008-08 | PHASE2 |
| NCT01570582 | UNKNOWN | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer |
Korean Gynecologic Oncology Group |
2010-03 | PHASE2 |
| NCT00648648 | COMPLETED | Solid Tumors |
Merck Sharp & Dohme LLC |
2008-02-25 | PHASE1 |
| NCT01663285 | TERMINATED | Urothelial Cancer; Bladder Cancer |
University of Michigan Rogel Cancer Center |
2012-09 | PHASE2 |
| NCT01167816 | TERMINATED | Pancreatic Cancer |
University of Oklahoma |
2010-07 | PHASE1 |
| NCT01505413 | COMPLETED | Pancreatic Cancer |
Soonchunhyang University Hospital |
2011-01 | PHASE2 |
| NCT01236716 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Chinese Society of Lung Cancer |
2010-11 | PHASE2 |
| NCT01447225 | COMPLETED | Solid Tumors |
Merrimack Pharmaceuticals |
2011-10 | PHASE1 |
| NCT02808091 | TERMINATED | Extranodal NK-T-CELL LYMPHOMA |
National Cancer Centre, Singapore |
2011-03 | PHASE2 |
| NCT01298401 | COMPLETED | Pancreatic Cancer |
Radiation Therapy Oncology Group |
2012-02 | PHASE1 |
| NCT01472198 | COMPLETED | Pancreatic Cancer |
Gilead Sciences |
2011-11 | PHASE2 |
| NCT01063192 | UNKNOWN | Locally Advanced Pancreatic Cancer |
National Health Research Institutes, Taiwan |
2009-11 | PHASE2 |
| NCT01324258 | COMPLETED | Solid Tumours |
GlaxoSmithKline |
2011-01-24 | PHASE1 |
| NCT00842712 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Merck KGaA, Darmstadt, Germany |
2009-02 | PHASE2 |
| NCT01929421 | COMPLETED | Advanced Colorectal Cancer |
Gachon University Gil Medical Center |
2009-12 | PHASE2 |
| NCT01352494 | UNKNOWN | Breast Cancer Stage II; Breast Cancer Stage III |
Korean Breast Cancer Study Group |
2011-05 | PHASE2 |
| NCT01641575 | TERMINATED | Solid Tumor; Non-small-cell Lung Cancer; Lung Cancer |
Clovis Oncology, Inc. |
2012-07 | PHASE1 |
| NCT01684449 | COMPLETED | Advanced Soft Tissue Sarcoma |
Grupo Espanol de Investigacion en Sarcomas |
2010-01 | PHASE1; PHASE2 |
| NCT01633645 | COMPLETED | Non Small Cell Lung Cancer; Metastatic |
University Hospital of Crete |
2009-06 | PHASE2 |
| NCT00655785 | COMPLETED | Pancreatic Cancer |
Fukushima Medical University |
2007-09 | PHASE1; PHASE2 |
| NCT00639925 | UNKNOWN | Pancreatic Cancer |
Fukushima Medical University |
2007-03 | PHASE1 |
| NCT00438204 | TERMINATED | Lung Cancer |
Barbara Ann Karmanos Cancer Institute |
2006-05 | PHASE2 |
| NCT01096745 | TERMINATED | Metastatic Biliary Tract Cancer; Locally Advanced Biliary Tract Cancer |
Gyeongsang National University Hospital |
2010-07 | PHASE2 |
| NCT01251640 | COMPLETED | Pancreatic Neoplasms |
Bayer |
2011-01-01 | PHASE1; PHASE2 |
| NCT01282333 | TERMINATED | Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage III Pancreatic Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Bladder Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Transitional Cell Carcinoma of the Bladder; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer |
National Cancer Institute (NCI) |
2011-01 | PHASE1 |
| NCT00634725 | COMPLETED | Pancreatic Cancer |
GERCOR - Multidisciplinary Oncology Cooperative Group |
2008-02 | PHASE3 |
| NCT00810719 | COMPLETED | Pancreatic Cancer |
University of California, Davis |
2009-04 | PHASE2 |
| NCT01064622 | COMPLETED | Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2009-09-03 | PHASE2 |
| NCT00500422 | COMPLETED | Solid Tumors |
M.D. Anderson Cancer Center |
2005-01 | PHASE1 |
| NCT00169195 | COMPLETED | Diffuse Large Cell Lymphoma |
Lymphoma Study Association |
2003-04 | PHASE2 |
| NCT00082862 | UNKNOWN | Pancreatic Cancer |
The University of Texas Health Science Center, Houston |
2002-07 | PHASE2 |
| NCT01161186 | COMPLETED | Pancreatic Neoplasms; Pancreatic Cancer; Adenocarcinoma |
University of California, San Francisco |
2010-07 | PHASE1 |
| NCT01020006 | COMPLETED | Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer |
Pharmacyclics LLC. |
2009-11 | PHASE2 |
| NCT00109928 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2005-09 | PHASE2 |
| NCT01130142 | COMPLETED | Metastatic Pancreatic Cancer |
Infinity Pharmaceuticals, Inc. |
2010-04 | PHASE1; PHASE2 |
| NCT01151761 | TERMINATED | Cholangiocarcinoma; Hepatobiliary Neoplasm; Liver Cancer; Bile Duct Cancer; Cancer of Gallbladder |
Stanford University |
2011-01 | PHASE2 |
| NCT00867126 | TERMINATED | Pancreatic Cancer |
University of Texas Southwestern Medical Center |
2009-03-02 | EARLY_PHASE1 |
| NCT00789633 | COMPLETED | Pancreatic Cancer |
AB Science |
2008-11-25 | PHASE3 |
| NCT00588666 | COMPLETED | Myeloproliferative Disorder; Urothelial Carcinoma; Cancer |
Memorial Sloan Kettering Cancer Center |
2006-05 | PHASE2 |
| NCT00771810 | COMPLETED | Thrombocytopenia; Neutropenia; Lymphopenia; Anemia |
Tarix Pharmaceuticals |
2008-10 | PHASE2 |
| NCT00846027 | COMPLETED | Breast Cancer |
Hoffmann-La Roche |
2009-01 | PHASE2 |
| NCT00714948 | TERMINATED | Bladder Cancer; URINARY BLADDER |
Memorial Sloan Kettering Cancer Center |
2008-07 | PHASE2 |
| NCT01218880 | UNKNOWN | Pancreatic Cancer |
Beijing Protgen Biotechnology Development Co., Ltd. |
2010-06 | PHASE1 |
| NCT00601627 | COMPLETED | Pancreatic Cancer |
Alliance for Clinical Trials in Oncology |
2009-06 | PHASE2 |
| NCT00954005 | TERMINATED | Indolent Lymphoma |
German Low Grade Lymphoma Study Group |
2003-01 | PHASE1; PHASE2 |
| NCT00509665 | COMPLETED | Head and Neck Cancer |
Medical University of South Carolina |
2005-06 | PHASE2 |
| NCT00477035 | COMPLETED | Leukemia; Multiple Myeloma |
Sally Arai |
2006-05 | PHASE1 |
| NCT00938652 | COMPLETED | Breast Cancer |
Sanofi |
2009-07 | PHASE3 |
| NCT00696696 | COMPLETED | Pancreatic Cancer |
NYU Langone Health |
2007-09 | PHASE2 |
| NCT00660725 | COMPLETED | Advanced Incurable Solid Malignancy |
Leonard Appleman |
2009-02 | PHASE1 |
| NCT02146703 | COMPLETED | Biliary Tract Neoplasm |
Hallym University Medical Center |
2005-08 | PHASE2 |
| NCT00673179 | TERMINATED | Osteosarcoma |
M.D. Anderson Cancer Center |
2008-05 | |
| NCT00114244 | COMPLETED | Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2004-12 | PHASE2 |
| NCT00662129 | COMPLETED | Breast Cancer |
Alliance for Clinical Trials in Oncology |
2008-11 | PHASE2 |
| NCT00783172 | TERMINATED | Pancreatic Cancer |
Milton S. Hershey Medical Center |
2009-01 | PHASE1 |
| NCT00661830 | COMPLETED | Adenocarcinoma |
PD Dr Markus Möhler |
2008-05 | PHASE2 |
| NCT00778128 | COMPLETED | Solid Tumors |
Clavis Pharma |
2008-10 | PHASE1 |
| NCT00449033 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Bayer |
2007-02 | PHASE3 |
| NCT00837031 | COMPLETED | Metastatic Pancreatic Cancer |
SCRI Development Innovations, LLC |
2009-02 | PHASE2 |
| NCT00833859 | TERMINATED | Pancreatic Neoplasms |
H. Lee Moffitt Cancer Center and Research Institute |
2009-03 | PHASE2 |
| NCT00456261 | COMPLETED | Lung Cancer |
SCRI Development Innovations, LLC |
2007-03 | PHASE2 |
| NCT00832689 | COMPLETED | Biliary Tract Cancer |
Yonsei University |
2008-06 | PHASE2 |
| NCT00073983 | COMPLETED | Sarcoma |
Sarcoma Alliance for Research through Collaboration |
2006-10 | PHASE2 |
| NCT00493441 | TERMINATED | Pancreatic Cancer |
Vertex Pharmaceuticals Incorporated |
2007-06 | PHASE2 |
| NCT00570713 | COMPLETED | Pancreatic Cancer |
Morphotek |
2007-12 | PHASE2 |
| NCT00625352 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Ulsan University Hospital |
2008-02 | PHASE2 |
| NCT00436280 | COMPLETED | Lymphoma, Large Cell, Diffuse |
Eli Lilly and Company |
2007-02 | PHASE2 |
| NCT00201760 | COMPLETED | Breast Cancer |
Kari Kendra |
2005-02-25 | PHASE2 |
| NCT00452881 | UNKNOWN | Lung Cancer |
National Cancer Center, Korea |
2006-05 | PHASE2 |
| NCT00844688 | UNKNOWN | Hepatocellular Carcinoma |
Combined Military Hospital, Pakistan |
2008-09 | PHASE2 |
| NCT00906061 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Hospital Arnau de Vilanova |
2007-10 | PHASE2 |
| NCT00327327 | COMPLETED | Pancreatic Adenocarcinoma |
AmpliMed Corporation |
2004-02 | PHASE1 |
| NCT00593008 | TERMINATED | Pancreatic Adenocarcinoma |
Massachusetts General Hospital |
2007-10 | PHASE1 |
| NCT00215930 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
H. Lee Moffitt Cancer Center and Research Institute |
2004-02 | PHASE2 |
| NCT00101283 | COMPLETED | Mesothelioma |
Eastern Cooperative Oncology Group |
2006-02-23 | PHASE2 |
| NCT00860015 | COMPLETED | Sarcoma, Soft Tissue |
Columbia University |
2005-08 | PHASE2 |
| NCT00960284 | COMPLETED | Pancreatic Cancer |
IRCCS San Raffaele |
2003-06 | PHASE2; PHASE3 |
| NCT00354549 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2006-01 | PHASE2 |
| NCT00859469 | COMPLETED | Mesothelioma |
Columbia University |
2004-04 | PHASE2 |
| NCT00337259 | TERMINATED | Non-Hodgkin's Lymphoma; Marginal Zone Lymphoma |
Asan Medical Center |
2006-06 | PHASE2 |
| NCT00744640 | COMPLETED | Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer |
University Hospital, Basel, Switzerland |
2005-10 | PHASE1; PHASE2 |
| NCT00470249 | TERMINATED | Breast Cancer |
University of Southampton |
2006-07-15 | PHASE2 |
| NCT00191152 | COMPLETED | Breast Cancer; Breast Neoplasms; Cancer of the Breast |
Eli Lilly and Company |
2002-02 | PHASE3 |
| NCT00191139 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2003-03 | PHASE2 |
| NCT00191451 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2004-04 | PHASE2 |
| NCT02004093 | COMPLETED | Ovarian Cancer |
Hoffmann-La Roche |
2005-12 | PHASE2 |
| NCT00394147 | TERMINATED | Head and Neck Cancer |
Fox Chase Cancer Center |
2006-10 | PHASE2 |
| NCT00447122 | TERMINATED | Metastatic Pancreatic Cancer |
Brown University |
2007-03 | PHASE1 |
| NCT00047307 | COMPLETED | Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2002-08 | PHASE1 |
| NCT00100815 | COMPLETED | Pancreatic Cancer |
Roswell Park Cancer Institute |
2004-08 | PHASE2 |
| NCT00401570 | COMPLETED | Pancreatic Cancer |
AbbVie (prior sponsor, Abbott) |
2005-03 | PHASE2 |
| NCT00254904 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Pfizer |
2005-11 | PHASE3 |
| NCT00184093 | COMPLETED | Uterine Cervical Cancer |
University of Southern California |
1999-06 | PHASE1; PHASE2 |
| NCT00496301 | COMPLETED | Carcinoma, Renal Cell |
Spanish Oncology Genito-Urinary Group |
2006-11 | PHASE2 |
| NCT00636311 | COMPLETED | Hodgkin Disease |
Istituto Clinico Humanitas |
2008-02 | PHASE2 |
| NCT00610740 | COMPLETED | Cervical Cancer; Endometrial Cancer; Ovarian Cancer |
Masonic Cancer Center, University of Minnesota |
2006-07 | PHASE2 |
| NCT00372944 | COMPLETED | Pancreatic Cancer |
AstraZeneca |
2006-08 | PHASE2 |
| NCT00191269 | COMPLETED | Metastatic Breast Cancer |
Eli Lilly and Company |
2005-06 | PHASE2 |
| NCT00163761 | COMPLETED | Non-Hodgkin's Lymphoma; Hodgkin's Disease |
Bayside Health |
2002-12 | PHASE2 |
| NCT00330746 | COMPLETED | Advanced Non-Small Cell Lung Cancer |
National Cancer Institute, Naples |
2005-11 | PHASE2 |
| NCT00063570 | COMPLETED | Breast Cancer; Breast Neoplasms |
Eli Lilly and Company |
2003-07 | PHASE2 |
| NCT00305786 | COMPLETED | Lung Cancer |
University of Miami |
2005-08 | PHASE2 |
| NCT00401609 | COMPLETED | Small Cell Lung Cancer |
National Cancer Institute, Naples |
2000-11 | PHASE1; PHASE2 |
| NCT00288925 | COMPLETED | Pancreatic Cancer |
Zeria Pharmaceutical |
2005-09 | PHASE1; PHASE2 |
| NCT00052689 | COMPLETED | Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2002-12 | PHASE2 |
| NCT00397787 | COMPLETED | Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2006-11 | PHASE2 |
| NCT00202800 | COMPLETED | Pancreatic Cancer |
Corewell Health West |
2002-03 | PHASE2 |
| NCT00336648 | COMPLETED | Pancreatic Neoplasms |
M.D. Anderson Cancer Center |
2006-06 | PHASE2 |
| NCT00307255 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
UNC Lineberger Comprehensive Cancer Center |
2006-08 | PHASE1 |
| NCT00258739 | COMPLETED | Lung Neoplasms |
Sanofi |
2001-10 | PHASE2 |
| NCT00075751 | COMPLETED | Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2004-01 | PHASE2 |
| NCT01172470 | COMPLETED | Head and Neck Cancer |
University of Chicago |
2005-06 | PHASE2 |
| NCT00652054 | COMPLETED | Metastatic Pancreatic Cancer |
Taiho Oncology, Inc. |
2005-06 | PHASE2 |
| NCT00101907 | TERMINATED | Lung Cancer; Pancreatic Cancer; Esophageal Cancer |
Amgen |
2004-12 | PHASE1 |
| NCT00217282 | COMPLETED | Non-Small Cell Lung Cancer |
Mt. Sinai Medical Center, Miami |
2004-06 | PHASE2 |
| NCT00660140 | COMPLETED | Cholangiocarcinoma; Gallbladder Cancer |
Washington University School of Medicine |
2002-03 | PHASE2 |
| NCT00401492 | COMPLETED | Non Small Cell Lung Cancer |
National Cancer Institute, Naples |
2002-06 | PHASE2 |
| NCT00026104 | COMPLETED | Adenocarcinoma of the Pancreas; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer |
National Cancer Institute (NCI) |
2001-11 | PHASE2 |
| NCT00112528 | COMPLETED | Pancreatic Cancer |
Alliance for Clinical Trials in Oncology |
2005-06 | PHASE2 |
| NCT00055835 | COMPLETED | Bladder Cancer; Urethral Cancer |
SWOG Cancer Research Network |
2002-11 | PHASE2 |
| NCT00532285 | TERMINATED | Breast Cancer |
National Cancer Center, Korea |
2005-09 | PHASE2 |
| NCT00136175 | COMPLETED | Bladder Cancer |
University of Michigan Rogel Cancer Center |
1999-11 | PHASE2 |
| NCT00154739 | COMPLETED | Non-Small Cell Lung Cancer |
National Taiwan University Hospital |
1998-10 | PHASE2 |
| NCT00193362 | COMPLETED | Lung Cancer |
SCRI Development Innovations, LLC |
2004-06 | PHASE3 |
| NCT00077350 | COMPLETED | Recurrent Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2004-07 | PHASE2 |
| NCT00003727 | COMPLETED | Leukemia |
University of Maryland, Baltimore |
1999-03 | PHASE2 |
| NCT00217698 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2003-11 | PHASE2 |
| NCT00003851 | TERMINATED | Malnutrition; Pancreatic Cancer |
Columbia University |
1999-03 | |
| NCT00052338 | COMPLETED | Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2002-09 | PHASE1 |
| NCT00033241 | COMPLETED | Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
OSI Pharmaceuticals |
2001-07-23 | PHASE1 |
| NCT00176813 | COMPLETED | Pancreatic Cancer |
University of Michigan Rogel Cancer Center |
2003-03 | PHASE2 |
| NCT00005991 | COMPLETED | Breast Cancer |
M.D. Anderson Cancer Center |
1997-08-25 | PHASE2 |
| NCT00020774 | WITHDRAWN | Liver Cancer |
Jonsson Comprehensive Cancer Center |
1998-10 | PHASE2 |
| NCT00003202 | COMPLETED | Lung Cancer |
Wake Forest University Health Sciences |
1998-01 | PHASE1; PHASE2 |
| NCT00003426 | COMPLETED | Pancreatic Cancer |
Memorial Sloan Kettering Cancer Center |
1998-04 | PHASE1 |
| NCT00003587 | COMPLETED | Lung Cancer |
SWOG Cancer Research Network |
1998-10 | PHASE2 |
| NCT00003358 | COMPLETED | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Memorial Sloan Kettering Cancer Center |
1998-01 | PHASE1 |
| NCT00003589 | COMPLETED | Lung Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
1998-08 | PHASE3 |
| NCT00003378 | TERMINATED | Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Gynecologic Oncology Group |
1998-08 | PHASE1 |
| NCT00201305 | COMPLETED | Biliary Tract Disease |
National Health Research Institutes, Taiwan |
2002-07 | PHASE2 |
| NCT00003447 | UNKNOWN | Lung Cancer |
Istituto Nazionale per lo Studio e la Cura dei Tumori |
1998-07 | PHASE3 |
| NCT00019513 | COMPLETED | Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Lung Cancer; Lymphoma; Pancreatic Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
National Institutes of Health Clinical Center (CC) |
1998-08 | PHASE1 |
| NCT00398697 | COMPLETED | Neoplasms |
AEterna Zentaris |
2004-08 | PHASE1 |
| NCT00005926 | COMPLETED | Pancreatic Cancer; Pancreatic Neoplasm |
National Cancer Institute (NCI) |
2000-06 | PHASE2 |
| NCT00061477 | COMPLETED | Mesothelioma |
Eli Lilly and Company |
2002-12 | PHASE2 |
| NCT00191347 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2004-10 | PHASE2 |
| NCT00139971 | UNKNOWN | Lung Cancer |
West Japan Thoracic Oncology Group |
2001-12 | PHASE3 |
| NCT00168870 | UNKNOWN | Ocular Melanoma |
Charite University, Berlin, Germany |
2003-02 | PHASE2 |
| NCT00352859 | TERMINATED | Carcinoma, Renal Cell |
Bayer |
2006-08 | PHASE4 |
| NCT00061451 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Eli Lilly and Company |
2002-12 | PHASE2 |
| NCT00561054 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Grupo Portugues de Estudo do Cancro do Pulmao |
2007-03 | PHASE2 |
| NCT00491114 | COMPLETED | Bladder Neoplasms |
Eli Lilly and Company |
2003-07 | PHASE2 |
| NCT00275119 | UNKNOWN | Pancreatic Cancer |
GERCOR - Multidisciplinary Oncology Cooperative Group |
2003-11 | PHASE2 |
| NCT00261092 | COMPLETED | Pancreatic Neoplasms |
Sanofi |
2005-10 | PHASE2 |
| NCT00192712 | COMPLETED | Pancreatic Cancer |
Rambam Health Care Campus |
2002-11 | PHASE2; PHASE3 |
| NCT00115635 | COMPLETED | Prostate Cancer |
Herlev Hospital |
2005-03 | PHASE1; PHASE2 |
| NCT00736814 | UNKNOWN | Lung Cancer |
Yonsei University |
2008-06 | PHASE2 |
| NCT00020345 | COMPLETED | Stage IVA Pancreatic Cancer; Stage III Pancreatic Cancer; Adenocarcinoma of the Pancreas |
National Institutes of Health Clinical Center (CC) |
2000-09 | PHASE2 |
| NCT00563160 | UNKNOWN | Lung Neoplasms |
Hospital Authority, Hong Kong |
2005-05 | PHASE2 |
| NCT00003182 | UNKNOWN | Head and Neck Cancer |
Hope Cancer Institute, Inc. |
1997-03 | PHASE1; PHASE2 |
| NCT00490880 | COMPLETED | Bladder Cancer |
Eli Lilly and Company |
2003-11 | PHASE2 |
| NCT00055432 | TERMINATED | Ovarian Cancer; Peritoneal Cancer |
Eli Lilly and Company |
PHASE2 | |
| NCT00004100 | UNKNOWN | Lung Cancer |
Istituto Nazionale per lo Studio e la Cura dei Tumori |
1998-11 | PHASE3 |
| NCT00271271 | COMPLETED | Non Small Cell Lung Cancer |
Sanofi |
2003-06 | PHASE2 |
| NCT00191763 | COMPLETED | Carcinoma, Non-Small-Cell-Lung Cancer |
Eli Lilly and Company |
2002-11 | PHASE2 |
| NCT00003780 | UNKNOWN | Pancreatic Cancer |
Meyer Pharmaceuticals |
1998-12 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-04-14)
Check the
Gemcitabine
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.